Comparison of Superior vs Nasal/Temporal Laser Peripheral Iridotomy in Primary Angle Closure

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03187821

Enrollment

1000

Registered

2017-06-15

Start date

2012-09-30

Completion date

2015-01-31

Last updated

2017-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma, Angle-Closure

Brief summary

The purpose of this study is to determine if location of laser peripheral iridotomy (LPI) that is the standard of care treatment for angle closure glaucoma is related to changes in post-operative intraocular pressure (IOP), endothelial cell count,anterior chamber angle morphology and onset of new visual disturbances.

Detailed description

Study hypothesis: Location of laser peripheral iridotomy affects occurrence of post-operative dysphotopsia symptoms, intraocular pressure, anterior chamber angle morphology and corneal endothelial cell count Study design: Multicenter randomized, prospective, single masked trial Trial setting: Hospitals Trial type: Treatment Interventions: South Indian subjects aged 30 years or greater, with primary angle closure suspect (PACS) or primary angle closure/ primary angle closure glaucoma(PAC/PACG) will be randomized to either bilateral superior or nasal/temporal laser peripheral iridotomy. Subjects will undergo noninvasive testing and imaging studies to measure IOP, anterior chamber angle morphology and endothelial cell count and asked to answer a questionnaire at baseline and again at 2 weeks and 6 months after treatment Primary outcome measures: Occurrence of new self-reported general eye or dysphotopsia symptoms. Secondary outcome measures: intraocular pressure, anterior chamber and anterior chamber angle morphology, endothelial cell count.

Interventions

PROCEDURELaser peripheral iridotomy

location of laser peripheral iridotomy

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

30 Years to No maximum

Healthy volunteers

Inclusion criteria

* diagnosis of PACS or PAC/PACG in at least one eye

Exclusion criteria

* bilaterally pseudophakic * prior iridotomy, iridoplasty, or incisional glaucoma surgery in either eye * signs or symptoms consistent with acute angle closure at time of enrollment

Design outcomes

Primary

Measure	Time frame	Description
Occurrence of new self-reported general eye or dysphotopsia symptoms	6 Months	Questionnaire using a Likert scale

Secondary

Measure	Time frame	Description
Intraocular pressure	6 Months	measured in mmHg
Anterior chamber angle morphology	6 Months	measured in micrometers using anterior segment optical coherence tomography
Corneal endothelial cell count	6 Months	measured on a continuous scale
Choroidal thickness	6 Months	measured in micrometers using enhanced depth optical coherence tomography

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026